A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Phase 3

Recruiting

• Conditions: Systemic Lupus Erythematosus
• Interventions: Drug: DZP; Other: Placebo

• Registration Number: NCT06617325
• Lead Sponsor: UCB Biopharma SRL

Brief Summary

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-09-24
• Study First Submitted QC: 2024-09-24
• Study First Posted: 2024-09-27
• Study Start: 2024-11-21
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-15
• Last Update Posted: 2025-05-16
• Primary Completion: 2027-09-15
• Study Completion: 2027-09-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 450

Inclusion Criteria

• Study participant must be ≥16 years of age, unless restricted by local regulation, at the time of signing the Informed Consent form (ICF)

• Study participants who have moderate to severe disease activity due to either persisting active systemic lupus erythematosus (SLE) or due to an acute worsening of SLE in the scope of frequent relapsing-remitting SLE despite stable standard of care(SOC) medication defined as:

  a. Diagnosed with SLE at least 24 weeks before the Screening Visit by a qualified physician b. Classified by 2019 SLE European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE c. With serological evidence for SLE at Screening as demonstrated by at least 1 of the following: i) Evidence for anti-dsDNA (defined as evidence for anti-dsDNA antibodies in central laboratory) ii) Either complement C3 <lower limit of normal (LLN) OR complement C4 <LLN as measured by central laboratory iii) Antinuclear antibodies with a titer of at least 1:80 confirmed by central laboratory in combination with evidence of at least 1 of the following SLE typical autoantibodies:

  1. Anti-Smith (anti-Sm) antibodies (central laboratory or source verifiable history)

  2. Anti-Sjögren's syndrome antibody A (Anti-SSA) (Ro)/Anti-Sjögren's syndrome antibody B (anti-SSB) (La) autoantibodies (central laboratory)

  3. Historical evidence for anti-dsDNA antibodies

  4. Anti-ribonucleoprotein (RNP) autoantibodies (central laboratory) d. Moderately to severely active defined as:

     • British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade B in ≥2 organ systems and/or a BILAG 2004 Grade A in ≥1 organ systems at Screening and Baseline Visit AND
     • Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ≥6 at the Screening Visit AND
     • SLEDAI-2K without labs ≥4 at Baseline Visit e. Receiving the following standard of care (SOC) medications at stable dose:
     • Antimalarial treatment in combination with corticosteroids and/or immunosuppressants or as stand-alone treatment if justified OR
     • Treatment with corticosteroids and/or immunosuppressants if antimalarial treatment is not appropriate (ie, there is documented intolerance in medical history, documented lack of efficacy, contraindications, or lack of availability)

Exclusion Criteria

• Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric SLE) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition
• Study participant has a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins, or monoclonal antibodies. This includes systemic reactions due to latex allergy
• Study participant has a history of malignancy, except the following treated cancers: cervical carcinoma in situ (after complete resection [eg, curettage, electrodesiccation] not later than 4 weeks prior to the Screening Visit [V1]), basal cell carcinoma, or dermatological squamous cell carcinoma
• Study participant has an increased risk for thromboembolic events due to an ongoing heart disease or due to a medical device, including but not limited to vascular graft, valvular heart disease, atrial fibrillation, or a heart rhythm disorder
• Study participant has a mixed connective tissue disease, scleroderma, and/or overlap syndrome of these diseases with SLE
• Study participant has evidence of human immunodeficiency virus (HIV) infection, agammaglobulinemias, T-cell deficiencies, or human T-cell lymphotropic virus-1 infection at any time prior to or during the study
• Study participant has clinically significant active or latent infection
• Study participant had a reactivated latent infection (eg, cytomegalovirus, herpes simplex virus, or herpes zoster infection) or opportunistic infection (including but not limited to, pneumocystis, cytomegalovirus, or severe herpes zoster infection) within 12 weeks prior to the first study medication infusion (Visit 2) or is currently receiving suppressive therapy for an opportunistic infection
• Study participants who have received live/live attenuated vaccines within 6 weeks prior to the first study medication infusion
• Study participant has used the prohibited medications defined in the Protocol
• Study participant has previously been randomized within this study or has previously been assigned to treatment with dapirolizumab pegol (DZP) in a study evaluating DZP
• Study participant has participated in another study of an investigational medicinal product (IMP) within the previous 12 weeks or 5 half-lives of the IMP whatever is longer, or is currently participating in another study of an IMP
• Study participant has chronic kidney failure stage 4, manifested by estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2, or serum creatinine >2.5 mg/dL, or participant has proteinuria >3g/day, or protein:creatinine ratio >340 mg/mmol at the Screening Visit

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dapirolizumab pegol	DZP	Study participants will receive dapriolizumab pegol throughout the Treatment Period.
Placebo	Placebo	Study participants will receive placebo throughout the Treatment Period.

Primary Outcome Measures

Name	Time	Method
Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 48	Week 48	A study participant is a BICLA responder if all of the following is fulfilled: a. BILAG 2004 improvement without worsening, defined as BILAG 2004 Grade As at Baseline improved to B/C/D, BILAG 2004 Grade Bs at Baseline improved to C/D, and no BILAG 2004 worsening in other BILAG 2004 organ systems (that had BILAG 2004 Grade C/D/E at Baseline) such that there are no new BILAG 2004 Grades A nor greater than 1 new BILAG 2004 Grade(s) B; and b. No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI- 2K) total score compared to Baseline (defined as no increase in SLEDAI-2K total score); and c. No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline defined as ≤10 mm increase on a 100 mm visual analog scale Escape treatment intervention as indicated by investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward.

Secondary Outcome Measures

Name	Time	Method
Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 24	Week 24	A study participant is a BICLA responder if all of the following is fulfilled: a. BILAG 2004 improvement without worsening, defined as BILAG 2004 Grade As at Baseline improved to B/C/D, BILAG 2004 Grade Bs at Baseline improved to C/D, and no BILAG 2004 worsening in other BILAG 2004 organ systems (that had BILAG 2004 Grade C/D/E at Baseline) such that there are no new BILAG 2004 Grades A nor greater than 1 new BILAG 2004 Grade(s) B; and b. No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI- 2K) total score compared to Baseline (defined as no increase in SLEDAI-2K total score); and c. No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline defined as ≤10 mm increase on a 100 mm visual analog scale Escape treatment intervention as indicated by investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward.
Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 12	Week 12	A study participant is a BICLA responder if all of the following is fulfilled: a. BILAG 2004 improvement without worsening, defined as BILAG 2004 Grade As at Baseline improved to B/C/D, BILAG 2004 Grade Bs at Baseline improved to C/D, and no BILAG 2004 worsening in other BILAG 2004 organ systems (that had BILAG 2004 Grade C/D/E at Baseline) such that there are no new BILAG 2004 Grades A nor greater than 1 new BILAG 2004 Grade(s) B; and b. No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI- 2K) total score compared to Baseline (defined as no increase in SLEDAI-2K total score); and c. No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline defined as ≤10 mm increase on a 100 mm visual analog scale Escape treatment intervention as indicated by investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward.
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 48	During Treatment Period up to Week 48	Severe BILAG flare is defined as a BILAG 2004 Grade A in any system due to individual items that are new or worse qualifying for the Grade A.; Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index.
Achievement of LLDAS in ≥50% of post Baseline visits through Week 48	During Treatment Period up to Week 48	Low lupus disease activity state (LLDAS) is defined as: * No significant disease activity as per Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); SLEDAI-2K score ≤4 with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever); * No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at previous visit; * Physician's Global Assessment of Disease (PGA) ≤33 mm; * Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤7.5 mg per day; * Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol
Change from Baseline in SLEDAI-2K at Week 48	From Baseline (Day 1) to Week 48	SLEDAI-2K measures disease activity. Disease activity in the 30 days prior to and at the time point of the assessment shall be considered. It is a global index and includes 24 clinical symptoms and laboratory variables that are weighted by the type of manifestation, but not by severity or dynamic of the individual item. The total score falls between 0 and 105, with higher scores representing increased disease activity.
Achievement of BILAG 2004 improvement without worsening at Week 48	Week 48	BILAG 2004 improvement without worsening can be defined as A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.
Change from Baseline in PGA at Week 48	From Baseline (Day 1) to Week 48	Physician's Global Assessment of Disease (PGA), the investigator will rate the overall status of the study participant. The PGA of disease activity used will be a 100 mm linear scale without anchors. The very far left end is 'very good, asymptomatic and no limitation of normal activities'; the very far right end indicates 'severe disease'.
Achievement of SRI 4 response at Week 48	Week 48	The Systemic Lupus Erythematosus Responder Index-4 (SRI 4) define responders as (ie, all criteria must be met): * Reduction in SLEDAI-2K score of ≥4; * No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline; * No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline; * No worsening in the PGA compared to Baseline score; "no worsening" is defined as either no worsening or worsening \<10% of the full 100 mm visual analog scale (VAS).
Achievement of prevention of moderate/severe BILAG flares (moderate/severe BILAG flare-free) through Week 48	During Treatment Period up to Week 48	A BILAG severe flare is defined as a BILAG 2004 Grade A in any system due to individual items that are new or worse qualifying for the Grade A. Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index.; A BILAG moderate flare is defined as 2 or more BILAG 2004 Grade Bs due to individual items that are new or worse since previous visit and are qualifying for the Grade B in any system. Determination of items that are new or worse qualifying for the Grade B will be according to the supplementary information for the numerical scoring of the BILAG-2004 index.
Time to severe BILAG flare through Week 48	During Treatment Period up to Week 48	A BILAG severe flare is defined as a BILAG 2004 Grade A in any system due to individual items that are new or worse qualifying for the Grade A. Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index.
Time to moderate/severe BILAG flare through Week 48	During Treatment Period up to Week 48	A BILAG severe flare is defined as a BILAG 2004 Grade A in any system due to individual items that are new or worse qualifying for the Grade A. Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index.; A BILAG moderate flare is defined as 2 or more BILAG 2004 Grade Bs due to individual items that are new or worse since previous visit and are qualifying for the Grade B in any system.; Determination of items that are new or worse qualifying for the Grade B will be according to the supplementary information for the numerical scoring of the BILAG-2004 index.
Percentage of participants with treatment-emergent adverse events (TEAEs) during the study	From Baseline (Day 1) until Safety Follow-Up (up to Week 54)	An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication.
Percentage of participants with serious treatment-emergent adverse events during the study	From Baseline (Day 1) until Safety Follow-Up (up to Week 54)	A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: 1. Results in death; 2. Is life-threatening; 3. Requires inpatient hospitalization or prolongation of existing hospitalization; 4. Results in persistent disability/incapacity; 5. Is a congenital anomaly/birth defect; 6. Is an Important medical event
Percentage of participants with treatment-emergent adverse events of special interest during the study	From Baseline (Day 1) until Safety Follow-Up (up to Week 54)	An adverse event of special interest is any adverse event (AE) that a regulatory authority has mandated be reported on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the administration of a UCB product/compound.
Percentage of participants with treatment-emergent adverse events of special monitoring during the study	From Baseline (Day 1) until Safety Follow-Up (up to Week 54)	An adverse event of special monitoring is a product-specific adverse event (AE), adverse reaction, or safety topic considered as requiring special monitoring by UCB.

Trial Locations

Locations (132)

Sl0044 20099; 🇨🇳 Taipei City, Taiwan

Sl0044 20082; 🇨🇳 Taiyuan CITY, Taiwan

Sl0044 40078; 🇩🇪 Leipzig, Germany

Sl0044 20287; 🇯🇵 Nagoya, Japan

Sl0044 40103; 🇪🇸 Sevilla, Spain

Sl0044 50285; 🇺🇸 Lake Charles, Louisiana, United States

Sl0044 20142; 🇨🇳 Taichung City, Taiwan

Sl0044 20080; 🇨🇳 Taichung, Taiwan

Sl0044 50660; 🇺🇸 New Orleans, Louisiana, United States

Sl0044 50058; 🇺🇸 Avondale, Arizona, United States

Sl0044 50550; 🇺🇸 Chandler, Arizona, United States

Sl0044 50052; 🇺🇸 Phoenix, Arizona, United States

Sl0044 50670; 🇺🇸 Searcy, Arkansas, United States

Sl0044 50275; 🇺🇸 La Palma, California, United States

Sl0044 50258; 🇺🇸 Los Angeles, California, United States

Sl0044 50340; 🇺🇸 Orange, California, United States

Sl0044 50316; 🇺🇸 San Leandro, California, United States

Sl0044 50630; 🇺🇸 Clearwater, Florida, United States

Sl0044 50681; 🇺🇸 Miami, Florida, United States

Sl0044 50698; 🇺🇸 Tampa, Florida, United States

Sl0044 50566; 🇺🇸 Gainesville, Georgia, United States

Sl0044 50659; 🇺🇸 Marietta, Georgia, United States

Sl0044 50699; 🇺🇸 Chicago, Illinois, United States

Sl0044 20136; 🇨🇳 Tianjin, China

Sl0044 50219; 🇺🇸 Detroit, Michigan, United States

Sl0044 50010; 🇺🇸 Brooklyn, New York, United States

Sl0044 50264; 🇺🇸 Manhasset, New York, United States

Sl0044 50077; 🇺🇸 New York, New York, United States

Sl0044 50238; 🇺🇸 Charlotte, North Carolina, United States

Sl0044 50001; 🇺🇸 Jackson, Tennessee, United States

Sl0044 50693; 🇺🇸 Murfreesboro, Tennessee, United States

Sl0044 50562; 🇺🇸 Allen, Texas, United States

Sl0044 50688; 🇺🇸 Houston, Texas, United States

Sl0044 40139; 🇩🇪 Jena, Germany

Sl0044 50696; 🇺🇸 Houston, Texas, United States

Sl0044 50036; 🇺🇸 Mesquite, Texas, United States

Sl0044 50061; 🇺🇸 Spokane, Washington, United States

Sl0044 60004; 🇦🇷 C.a.b.a, Argentina

Sl0044 60002; 🇦🇷 Capital Federal, Argentina

Sl0044 60029; 🇦🇷 Mendoza, Argentina

Sl0044 60003; 🇦🇷 Quilmes, Argentina

Sl0044 60011; 🇦🇷 San Juan, Argentina

Sl0044 60014; 🇦🇷 Tucuman, Argentina

Sl0044 40002; 🇧🇪 Leuven, Belgium

Sl0044 20293; 🇨🇳 Baotou, China

Sl0044 20128; 🇨🇳 Beijing, China

Sl0044 20157; 🇨🇳 Beijing, China

Sl0044 20173; 🇨🇳 Beijing, China

Sl0044 20201; 🇨🇳 Bengbu, China

Sl0044 20186; 🇨🇳 Chang ZHOU, China

Sl0044 40716; 🇩🇪 Köln, Germany

Sl0044 20291; 🇨🇳 Changchun, China

Sl0044 20295; 🇨🇳 Changsha, China

Sl0044 20019; 🇨🇳 Guangzhou, China

Sl0044 20290; 🇨🇳 Guilin, China

Sl0044 20271; 🇨🇳 Haikou, China

Sl0044 20296; 🇨🇳 Hangzhou, China

Sl0044 20185; 🇨🇳 Jinan, China

Sl0044 20192; 🇨🇳 Nanchang, China

Sl0044 20024; 🇨🇳 Nanjing, China

Sl0044 20272; 🇨🇳 Pingxiang, China

Sl0044 20020; 🇨🇳 Shanghai, China

Sl0044 20172; 🇨🇳 Shanghai, China

Sl0044 20204; 🇨🇳 Suzhou, China

Sl0044 20275; 🇨🇳 Urumuqi, China

Sl0044 20025; 🇨🇳 Wenzhou, China

Sl0044 20180; 🇨🇳 Wuhan, China

Sl0044 20270; 🇨🇳 Wuhan, China

Sl0044 20274; 🇨🇳 Xi'an, China

Sl0044 20273; 🇨🇳 Yangzhou, China

Sl0044 20132; 🇨🇳 Zhengzhou, China

Sl0044 40513; 🇩🇰 Copenhagen, Denmark

Sl0044 40489; 🇩🇰 Odense, Denmark

Sl0044 40386; 🇩🇪 Cologne, Germany

Sl0044 40322; 🇩🇪 DESSAU-ROßLAU, Germany

Sl0044 40356; 🇩🇪 Dresden, Germany

Sl0044 40072; 🇩🇪 Freiburg, Germany

Sl0044 40717; 🇩🇪 Greifswald, Germany

Sl0044 40027; 🇩🇪 Herne, Germany

Sl0044 40715; 🇩🇪 Vogelsang-gommern, Germany

Sl0044 40376; 🇬🇷 Athens, Greece

Sl0044 40501; 🇬🇷 Athens, Greece

Sl0044 40377; 🇬🇷 Heraklion, Greece

Sl0044 40507; 🇬🇷 Larissa, Greece

Sl0044 40514; 🇮🇹 Genova, Italy

Sl0044 40291; 🇮🇹 Milano, Italy

Sl0044 40471; 🇮🇹 Milano, Italy

Sl0044 40509; 🇮🇹 Padova, Italy

Sl0044 40148; 🇮🇹 Roma, Italy

Sl0044 20035; 🇯🇵 Bunkyo-ku, Japan

Sl0044 20196; 🇯🇵 Bunkyo-ku, Japan

Sl0044 20279; 🇯🇵 Bunkyo-ku, Japan

Sl0044 20030; 🇯🇵 Chuo-ku, Japan

Sl0044 20281; 🇯🇵 Fukuoka, Japan

Sl0044 20282; 🇯🇵 Fukuoka, Japan

Sl0044 20039; 🇯🇵 Kawagoe, Japan

Sl0044 20045; 🇯🇵 Kita-gun, Japan

Sl0044 20065; 🇯🇵 Kitakyushu, Japan

Sl0044 20069; 🇯🇵 Meguro-ku, Japan

Sl0044 20071; 🇯🇵 Nagasaki, Japan

Sl0044 20283; 🇯🇵 Sagamihara, Japan

Sl0044 20084; 🇯🇵 Saga, Japan

Sl0044 20031; 🇯🇵 Sapporo, Japan

Sl0044 20042; 🇯🇵 Sasebo, Japan

Sl0044 20171; 🇯🇵 Sendai-shi, Japan

Sl0044 20076; 🇯🇵 Shinjuku-ku, Japan

Sl0044 20086; 🇨🇳 Taipei City, Taiwan

Sl0044 20285; 🇯🇵 Shinjuku-ku, Japan

Sl0044 20032; 🇯🇵 Suita, Japan

Sl0044 20277; 🇯🇵 Suita, Japan

Sl0044 20278; 🇯🇵 TSU, Japan

Sl0044 20276; 🇯🇵 Yoshida-gun, Japan

Sl0044 20141; 🇰🇷 Busan, Korea, Republic of

Sl0044 20104; 🇰🇷 Seoul, Korea, Republic of

Sl0044 20092; 🇰🇷 Suwon-si, Korea, Republic of

Sl0044 40838; 🇳🇱 Amsterdam, Netherlands

Sl0044 40398; 🇵🇱 Katowice, Poland

Sl0044 40502; 🇵🇱 Krakow, Poland

Sl0044 40044; 🇵🇱 Poznan, Poland

Sl0044 40821; 🇵🇱 Poznan, Poland

Sl0044 40097; 🇵🇱 Warszawa, Poland

Sl0044 40098; 🇵🇱 Warszawa, Poland

Sl0044 40481; 🇵🇱 Wroclaw, Poland

Sl0044 50671; 🇵🇷 Caguas, Puerto Rico

Sl0044 50683; 🇵🇷 San Juan, Puerto Rico

Sl0044 40466; 🇷🇸 Kragujevac, Serbia

Sl0044 40392; 🇷🇸 Novi Sad, Serbia

Sl0044 40045; 🇪🇸 A Coruna, Spain

Sl0044 40826; 🇪🇸 Badajoz, Spain

Sl0044 40160; 🇪🇸 Barcelona, Spain

Sl0044 40341; 🇪🇸 Málaga, Spain

Sl0044 40101; 🇪🇸 Sabadell, Spain